Answers are grounded in this paper and cite their sources.
In vitro analysis shows sparfloxacin and its combination with efflux pump blockers reduce MRSA and E. coli resistance.
Background: Multi-drug resistance has emerged as a significant global health challenge that has resulted in the occurrence of numerous diseases. This paper highlighted the potential of Sparfloxacin as a solution to antimicrobial resistance when used alone or in combination with efflux pump blockers. Sparfloxacin is a fluoroquinolone antibiotic that inhibits the bacterial DNA gyrase, thereby preventing DNA replication. The purpose of this study was to determine the efficacy of Sparfloxacin against MRSA and E. coli, and whether it could be used either solely or in combination with the efflux pump blockers to overcome multidrug resistance. Methods: The study targeted two pathogens, Methicillin-Resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli). The research methods included the determination of Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) values of Sparfloxacin solely, and in combination with Tamoxifen and Verapamil. The study was conducted over a time period of one year, and the study design was basic. Result: The effective concentration of Sparfloxacin was found to be 0.001µg/ml for MRSA and 5µg/ml for E. coli. Whereas, when used in combination with the efflux pump blocker, the effective concentration was found to be 0.31µg/ml with 128µg/ml of Tamoxifen for both the microbes. Verapamil with Sparfloxacin (0.31µg/ml) was found to be effective with 24µg/ml as MBC, and 12µg/ml as MIC value against Methicillin-Resistant Staphylococcus aureus. For E. coli, the MBC value of Verapamil with Sparfloxacin (20µg/ml) was found to be 166.66µg/ml. Conclusion: The study suggested that Sparfloxacin could be a potential solution to multidrug resistance, even when used solely, unlike other antibiotics, which show better efficacy at higher concentrations. Tamoxifen and Verapamil can be used with other antibiotics to enhance their efficacy against the multidrug-resistant strains.
No takes yet. Share an insight, caveat, or question.
Tahir et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: